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y 30, 2013.his study sought to ascertain whether high-dose allopurinol causes regression of left ventricular mass (LVM) in
patients with type 2 diabetes mellitus (T2DM).Background Left ventricular hypertrophy (LVH) is common in T2DM and contributes to patients’ high cardiovascular (CV) event
rate. Oxidative stress (OS) has been implicated in LVH development, and allopurinol has been previously shown to
reduce vascular OS. We therefore investigated whether allopurinol causes regression of LVH in patients with T2DM.Methods We conducted a randomized, double-blind, placebo-controlled study of 66 optimally-treated T2DM patients with
echocardiographic evidence of LVH. Allopurinol, 600 mg/day, or placebo was given over the study period of 9
months. The primary outcome was reduction in LVM as calculated by cardiac magnetic resonance imaging at
baseline and at 9 months’ follow-up. Secondary endpoints were change in ﬂow-mediated dilation and augmentation
index.Results Allopurinol signiﬁcantly reduced absolute LVM (2.65  5.91 g vs. placebo group þ1.21  5.10 g [p ¼ 0.012]) and
LVM indexed to body surface area (1.32  2.84 g/m2 vs. placebo group þ0.65  3.07 g/m2 [p ¼ 0.017]). No
signiﬁcant changes were seen in either ﬂow-mediated dilation or augmentation index.Conclusions Allopurinol causes regression of LVM in patients with T2DM and LVH. Regression of LVH has been shown previously
to improve CV mortality and morbidity. Therefore, allopurinol therapy may become useful to reduce CV events in
T2DM patients with LVH. (Allopurinol in Patients with Diabetes and LVH; UKCRN 8766) (J Am Coll Cardiol
2013;62:2284–93) ª 2013 by the American College of Cardiology FoundationType 2 diabetes mellitus (T2DM) reduces life expectancy by
8 to 10 years (1–3). It is thought that up to 70% of deaths are
due to cardiovascular (CV) disease, due mainly to an excess
of CV events (4,5). Left ventricular hypertrophy (LVH) is
common (40% to 70% event rate) in T2DM and is a strong
independent predictor of CV events, CV deaths, and total
mortality (6,7). In the only head-to-head comparison study,
LVH was, in fact, a stronger risk factor and accounted for
more deaths than multivessel coronary artery disease (8). Inar and Diabetes Medicine, Medical Research
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13; revised manuscript received July 4, 2013,fact, the independent risk ratio for LVH is consistently
approximately 2.5, irrespective of blood pressure (BP) (9,10).
The probable reason that LVH is so adverse is because it
pre-dates so many different adverse sequelae. For example,
LVH reduces coronary ﬂow reserve and, hence, induces
ischemia (11–13). LVH is intrinsically arrhythmogenic,
producing ventricular tachycardia and atrial ﬁbrillation (AF)
(14–16). LVH impedes left ventricular (LV) ﬁlling and,
hence, produces diastolic heart failure. Finally, LVH
increases left atrial size, which leads to AF and car-
dioembolic strokes (17,18).See page 2294Despite aggressive treatments for BP, LVH remains
a problem in patients with T2DM and is still common when
BP is controlled (19,20). Regression of LVH per se is known
to reduceCV events over and above BP control, and therefore,
CV events may well be reduced further in T2DM patients if
Figure 1 Outline of Study Visits
Flow chart showing patient involvement in the study. BNP ¼ B-type natriuretic
peptide; FBC ¼ full blood count; LDL ¼ low-density lipoprotein; LFT ¼ liver function
test; MRI ¼ magnetic resonance imaging; Trop ¼ troponin.
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2285we can ﬁnd novel ways to regress LVH (21). One new
possibility to regress LVH is allopurinol. Previous animal and
human studies have suggested that allopurinol might reduceleft ventricular mass (LVM). Our
group has recently shown that
allopurinol can cause regression of
LVM in chronic kidney disease
patients (22) and in patients with
optimally-treated ischemic heart
disease (23). Three additional
studies have also shown that
allopurinol can regress LVH in
various experimental models of
cardiac disease (24–26). We
therefore assessed whether, in
T2DM patients with LVH, allo-
purinol would really cause
regression of LVHover and above
traditional optimum therapy.Methods
Study overview. The study was
carried out as a single-center randomized, double-blind,
placebo-controlled trial with 9 months’ follow up. The
active drug was allopurinol, 600 mg/day, given as 300 mg
twice per day. It was approved by the Tayside Research
Ethics Committee and was carried out in accordance with
the Declaration of Helsinki.
Study participants. Patients were identiﬁed from the Scot-
tish Diabetes Research Network, the Health Informatics
Centre, or the Scottish Primary Care Research Network.
Patients with T2DM and ofﬁce BP <150/90 mm Hg who
attended for screening underwent echocardiography. LVH on
echocardiography was deﬁned by the American Society of
Echocardiography criteria as an LVM index of>115 g/m2 for
men and >95 g/m2 for women (using the average of 3
measurements of LVM by 1 trained operator [B.R.S.]) (27).
Exclusion criteria included gout, patients currently taking
allopurinol, previous adverse reaction to allopurinol,
estimated glomerular ﬁltration rate<60ml/min/1.73m2, con-
ditions that excluded magnetic resonance imaging (MRI),
LV ejection fraction <45%, cancer or other life-threatening
illness, pregnancy or breast feeding, and inability to provide
consent.
Sixty-six patients were recruited; 33 patients were ran-
domized to receive allopurinol, and 33 were randomized to
receive placebo. Patients were allocated by computer-
generated treatment code (patients and investigators were
blinded). Patients continued all other medications, including
antihypertensive and hypoglycemic agents.
Study visits and drug titration. After they were recruited,
patients attended for 6 visits over a 9-month period. An initial
dosage of allopurinol, 100 mg/day, or placebo was dispensed,
and this dosage of allopurinol was increased to 300 mg/day,
or placebo, after 2 weeks. The dosage was further increased
to 600 mg/day, or placebo, at 4 weeks and continued for the
duration of the trial. Study visits are outlined in Figure 1.
Ofﬁce BP was measured for all patients at each visit, and
Figure 2 Cardiac Magnetic Resonance Images for Left Ventricular Mass Estimation
An example of cardiac magnetic resonance images, highlighting typical endocardial and epicardial border region-of-interest contouring from a set of study images. In this
example, a total of 9 slices were acquired from the base of the left ventricular myocardium (top left) to the apex (bottom right).
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22869 randomly selected patients had a 24-h ambulatory BP
monitor at baseline and ﬁnal visit. Availability of ambulatory
monitors was limited, which is why 24-h BP was only
monitored in a random subset.
Cardiac MRI. Cardiac MRI was performed at baseline and
at 9 months only, using a 3-T Magnetom Trio scanner
(Siemens, Erlangen, Germany). Images were analyzed by an
independent MRI physicist with cardiac MRI experience,
using commercially available software (Argus version B15;
Siemens, Erlangen, Germany). Regions of interest were
placed around the left ventricular borders at end diastole
(Fig. 2) in order to derive LVM. Full details of the MRI
protocol are available in the Online Appendix.
Flow-mediated dilation. Endothelial function was
assessed by measuring ﬂow-mediated dilation (FMD) of the
brachial artery. FMD was measured using a Sequoia 512
(Siemens, Camberley, United Kingdom) ultrasonography
machine with an 8-MHz linear array probe. FMD was
performed at baseline and at 6 and 9 months (Fig. 1). The
response to hyperemia and endothelial independent dilationwas measured according to International Brachial Artery
Reactivity Task Force guidelines and has been performed
routinely at our institute (28–30). Our precise methodology
has been described in detail previously (22,23,31).
Applanation tonometry. Pulse wave analysis and pulse
wave velocity were measured at baseline and at 6 and 9
months by a single, trained investigator (B.R.S.) who was
blinded to the allocated treatment. Analysis was performed
using a SphygmoCor (AtCor, Sydney, Australia) machine
using a high-ﬁdelity micromanometer. Our methods were
published previously (22,23,31).
Statistical analysis. Using published data from Grothues
et al. (32), 60 were required patients to provide 90% power
to detect a 5-g difference in LVM between active drug and
placebo.
Data for continuous variables are presented as mean  SD.
Categorical data are expressed as percentages. Comparison
between continuous variables were analyzed using the Student
t test or Mann-Whitney U test, while categorical variables
were analyzed using the chi-square test. A multivariate
Figure 3 CONSORT Diagram
CONSORT diagram showing study recruitment numbers. BP ¼ blood pressure; CONSORT ¼ CONsolidated Standards of Reporting; LVH ¼ left ventricular hypertrophy; MRI ¼
magnetic resonance imaging.
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2287analysis of variance using important covariates was
also performed. All statistical analyses were undertaken using
SPSS software version 18.0 (SPSS, Inc., Chicago, Illinois). A
2-sided p value <0.05 was considered statistically signiﬁcant.
Endpoints. The primary endpoint was to assess whether
allopurinol caused regression of LVH in patients with
T2DM and controlled BP. The secondary endpoint was
to assess whether allopurinol improved parameters of end-
othelial function. The primary endpoint (LVH) was
measured only at 0 and 9 months, whereas the secondary
endpoint was measured at 0, 6, and 9 months.Results
In total, 66 patients were recruited, and 7 participants
withdrew from the study (placebo n ¼ 3, allopurinol n ¼ 4)(Fig. 3). Another 4 participants were unable to undergo
cardiac MRI (placebo n ¼ 1, allopurinol n ¼ 3). Therefore,
56 participants completed the cardiac MRI parts of the trial,
and 59 completed all other tests. Baseline characteristics
are shown in Table 1. There were no signiﬁcant differences
for baseline characteristics other than for baseline body mass
index, stroke, and creatinine level.
The main ﬁnding from this study is that allopurinol
signiﬁcantly reduced LVM over the 9-month study period,
both for absolute LVM and left ventricular mass indexed to
body surface area (LVMI). Change in LVM was 2.65 
5.91 g and þ1.21  5.10 g (p ¼ 0.012) for the allopurinol
and placebo groups, respectively. Change in LVMI was
1.32  2.84 g/m2 and þ0.65  3.07 g/m2 (p ¼ 0.017)
for the allopurinol and placebo groups, respectively (Table 2,
Fig. 4). We performed a multivariate analysis of variance
Table 1 Baseline Characteristics
Variable All Patients Placebo Allopurinol p Value
Patients, total n ¼ 59 n ¼ 30 n ¼ 29
Did not have MRI 4 1 3
Completed MRI 56 29 26
Completed FMD 59 30 29
Age, yrs 64.63  8.79 66.03  8.86 63.17  8.64 0.214
Male 36 (61.02%) 21 (70.00%) 16 (55.17%) 0.101
BMI baseline 32.59  4.78 31.12  3.93 34.13  5.14 0.014
24-h SBP baseline, mm Hg 121.67  11.55 122.25  11.59 121.20  12.87 0.903
24-h DBP baseline, mm Hg 66.22  3.31 68.25  2.75 64.60  2.97 0.101
Ofﬁce SBP baseline, mm Hg 139.51  11.33 141.63  11.03 137.31  11.41 0.144
Ofﬁce DBP baseline, mm Hg 77.66  8.69 76.70  10.18 78.66  6.87 0.392
Echo LVMI, g/m2 126.18  19.04 126.39  17.46 125.97  20.88 0.933
Absolute MRI LVM, g (n ¼ 56) 122.60  28.32 119.92  27.89 125.59  29.36 0.464
MRI LVMI, g/m2 (n ¼ 56) 60.67  9.78 60.16  10.11 61.23  9.56 0.691
Hypertension 53 (89.83%) 27 (90.00%) 26 (89.66%) 0.534
IHD 6 (10.17%) 3 (10%) 3 (10.34%) 0.534
Stroke 6 (10.67%) 5 (16.67%) 1 (3.45%) 0.026
Raised cholesterol 54 (91.52%) 27 (90.00%) 27 (93.10%) 0.056
Smoker 8 (13.56%) 6 (20.00%) 2 (6.90%) 0.454
Ex-smoker 26 (44.07%) 11 (36.66%) 15 (51.72%) 0.518
Never smoked 25 (42.37%) 13 (43.33%) 12 (41.38%) 0.638
Duration of diabetes, yrs 9.46  6.02 8.97  5.36 9.97  6.68 0.528
ACE inhibitor 29 (49.15%) 13 (43.33%) 16 (55.17%) 0.363
ARB 16 (27.12%) 8 (36.67%) 8 (27.59%) 0.937
CCB 16 (27.12%) 11 (36.67%) 5 (17.24%) 0.093
Thiazide diuretic 13 (22.03%) 8 (26.67%) 5 (17.24%) 0.383
Furosemide 4 (6.78%) 3 (10.00%) 1 (3.45%) 0.317
Beta-blocker 14 (23.73%) 7 (23.33%) 7 (24.14%) 0.942
Metformin 45 (76.27%) 20 (66.67%) 25 (86.21%) 0.078
Gliclazide 15 (24.42%) 7 (23.33%) 8 (27.58%) 0.708
TZD 7 (11.86%) 3 (10.00%) 4 (13.79%) 0.652
Exenatide 2 (3.39%) 0 (0.00%) 2 (6.90%) 0.143
Insulin 9 (15.25%) 4 (13.33%) 5 (17.24%) 0.676
Aspirin 28 (47.46%) 15 (50.00%) 13 (44.53%) 0.691
Clopidogrel 2 (3.39%) 0 (0.00%) 2 (6.90%) 0.143
Statin 50 (84.75%) 25 (83.33%) 28 (86.21%) 0.759
Hemoglobin, g/l 13.73  1.43 14.06  1.27 13.40  1.53 0.076
eGFR, ml/min/1.73 m2 86.31  13.75 83.21  10.38 89.52  16.09 0.078
Creatinine, mm/l 76.88  12.08 80.00  11.16 73.66  12.33 0.043
Fasting glucose, mmol/l 6.62  1.96 6.14  1.66 7.11  2.15 0.056
Fasting insulin, mU/l 32.16  25.34 34.37  27.74 29.88  22.87 0.501
HbA1c, % 7.25  0.94 7.12  0.83 7.39  1.04 0.274
Urine PCR, mg/mmol 13.05  8.26 14.13  10.51 11.93  4.93 0.310
BNP, pg/ml 29.01  25.81 30.01  22.74 27.97  29.03 0.764
Uric acid, mmol/l 0.54  0.13 0.54  0.10 0.55  0.15 0.613
HS TropT, ng/l 7.46  4.85 7.90  5.59 7.01  3.99 0.486
Oxidized LDL, U/l 28.51  9.90 27.58  10.07 29.48  9.81 0.467
EF, % 75.15  5.317 75.21  4.66 75.08  5.78 0.927
EDV, ml 123.52  35.94 118.36  36.41 129.28  35.23 0.264
ESV, ml 31.17  13.01 29.80  12.00 32.71  14.12 0.412
SV, ml 92.36  25.42 88.57  26.06 96.58  24.50 0.247
CO, ml 6.41  1.60 6.18  1.70 6.66  1.47 0.265
FMD, % 4.11  0.08 4.16  0.59 4.07  0.64 0.578
AIx, % 11.09  10.07 10.47  10.78 11.76  9.40 0.629
PWV (m/s) 7.07  1.14 6.94  1.03 7.19  1.24 0.468
Values are n, mean  SD, or n (%). ACE ¼ angiotensin-converting enzyme; AIx ¼ augmentation index; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide; CCB ¼
calcium-channel blocker; CO ¼ cardiac output; DBP ¼ diastolic blood pressure; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; eGFR ¼ estimated glomerular ﬁltration rate; ESV ¼ end-systolic volume;
FMD ¼ ﬂow-mediated dilation; HbA1c¼ glycosylated hemoglobin; HS¼ high sensitivity; IHD ¼ ischemic heart disease; LDL ¼ low-density lipoprotein; LVM ¼ left ventricular mass; LVMI ¼ left ventricular mass
index; MRI ¼ magnetic resonance imaging; PCR ¼ protein creatinine ratio; PWV ¼ pulsed wave velocity; SBP ¼ systolic blood pressure; SV ¼ stroke volume; TropT ¼ troponin T; TZD ¼ thiazolidinediones.
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Table 2
Change in MRI Parameters Over the 9-Month Study
Period
Change Placebo Allopurinol p Value
LVM, g þ1.21  5.10 2.65  5.91 0.012
LVMI, g/m2 þ0.65  3.07 1.32  2.84 0.017
EF, ml 0.08  7.41 1.46  6.10 0.458
EDV, ml 4.45  39.60 6.12 40.57 0.878
ESV, ml 2.44  21.84 0.20  14.60 0.660
SV, ml 2.01  24.83 5.89  28.88 0.595
CO, l/min 0.75  1.61 0.67  1.45 0.081
Values are mean  SD.
Abbreviations as in Table 1.
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2289using covariates of baseline BP, change in BP, and
prescription of angiotensin-converting enzyme inhibitor or
angiotensin receptor blockers, and this still showed a signif-
icant difference between allopurinol and placebo (p ¼ 0.013
for LVM and p ¼ 0.021 for LVMI). Allopurinol-induced
LVH regression, however, was concentrated in those with
an above-median LVMI at baseline, as might be expected,
as shown in Tables 3 and 4 and Figures 5 and 6. Interest-
ingly, in the placebo group, LVH appeared to progress more
in the group with the above-median LVH at baseline (i.e.,
the same group that regressed more with allopurinol).
Results are detailed further in Table 2 and in Figures 5 and
6. It is quite common for LVM to increase with ageing in
the placebo group of MRI studies, as we saw here and have
seen previously (31).
For the other parameters measured on cardiac MRI,
there were no signiﬁcant changes in ejection fraction, end-
diastolic volume, end-systolic volume, stroke volume, and
cardiac output (Table 2). There was no change in brain
natriuretic peptide, oxidized low-density lipoprotein (LDL),
or high-sensitivity troponin over the study period (Table 5).
There was, as expected, a signiﬁcant reduction in uric acid
levels in the allopurinol group. The allopurinol dosage
we used was safe, and there were no changes in urine
protein/creatinine ratio or estimated glomerular ﬁltration
rate. There were no differences in the change in ofﬁce or
24-h BP over time (Table 6) and no differences in BP
between those with high versus those with low LVM. No
signiﬁcant changes were seen in FMD and augmentation





(LVM Above Median) p Va
LVM, g 2.67  4.87 4.03  6.77 0.0
LVMI, g/m2 1.32  2.13 1.93  3.09 0.0
EF, ml 0.64  9.17 0.26  5.48 0.9
EDV, ml 0.75  44.45 5.81  40.28 0.6
ESV, ml 3.09  30.63 1.78  15.00 0.8
SV, ml 3.83  21.28 3.99  27.90 0.4
CO, l/min 0.23  1.65 0.68  1.07 0.1
Values are mean  SD.
Abbreviations as in Table 1.The reasons for withdrawing from and not completing
the trial are outlined in the CONsolidated Standards of
Reporting Trials (CONSORT) diagram in Figure 3.Discussion
We have shown that allopurinol causes regression of LVH
in patients with T2DM and LVH, especially, as might be
expected, in those with higher baseline LV masses. These
results agree with those of previous studies of ischemic heart
disease (23) and chronic kidney disease, in which allopurinol
also caused regression of LVH without changing BP (22).
This ﬁnding is also consistent with 3 experimental studies in
animal models that also showed LVH regression with
allopurinol (24–26). This would make allopurinol the ﬁrst
“non-antihypertensive drug” conclusively shown to induce
regression of LVH in humans in a wide spectrum of
diseases, which now includes diabetes mellitus.
Regression of LVH normally decreases CV morbidity and
mortality irrespective of BP changes (33). The largest trial to
show this is the LIFE (Losartan Intervention for Endpoint
Reduction in Hypertension) trial, which studied hyperten-
sive patients with evidence of electrocardiographically-
deﬁned LVH (34,35). In the LIFE study, Devereux et al.
(35) found that LVH regression per se (independent of BP)
was associated with substantial reduction in all-cause
mortality, CV mortality, sudden cardiac death, myocardial
infarction, new heart failure, new AF, and stroke (36–38).
It is worth considering why allopurinol should regress
LVH. Allopurinol reduces tissue oxidative stress (OS) (39),
and OS is a mediator of myocardial hypertrophy (40,41).
Therefore, hypothetically, the reduction in OS could
mediate LVH regression. Furthermore, Cingolani et al. (42)
showed that losartan, a uricosuric angiotensin receptor-1
antagonist, is able to reduce pressure overload LVH in
mice independently of arterial blood pressure and that this
effect was likely the result of a signiﬁcant reduction in
reactive oxygen species. This possibility also was demon-
strated in the La Plata study, in which oxypurinol reduced
LVH and improved LV ejection fraction in patients with
heart failure (43). The results of this present study are
aligned with these ﬁndings, which suggest that the reduction





(LVM Below Median) p Value
06 0.16  5.10 1.27  4.76 0.559
04 0.02  2.70 0.71  2.52 0.552
13 0.22  5.63 2.66  6.67 0.303
92 9.30  35.34 6.43  42.50 0.847
89 1.83  10.64 1.38  14.61 0.507
18 7.47  27.32 7.80  30.85 0.977
07 0.07  1.62 0.65  1.81 0.373









(LVMI Below Median) p Value
LVM, g 1.42  5.63 4.03  6.77 0.025 0.95  4.59 1.27  4.76 0.240
LVMI, g/m2 1.58  2.59 1.93  3.09 0.003 0.50  3.31 0.71  2.52 0.299
EF, ml 0.13  9.67 0.26  5.48 0.899 0.35  3.36 2.66  6.67 0.274
EDV, ml 1.44  41.48 5.81  40.28 0.778 8.16  38.48 6.43  42.50 0.062
ESV, ml 3.30  28.47 1.78  15.00 0.864 1.38  9.86 1.38  14.61 0.110
SV, ml 1.85  20.38 3.99  27.90 0.520 6.77  29.57 7.80  30.85 0.932
CO, l/min 0.18  1.65 0.68  1.07 0.117 0.06  1.63 0.65  1.81 0.383
Values are mean  SD.
Abbreviations as in Table 1.
Figure 4 Overall LV Change
Histogram of changes in (A) left ventricular (LV) mass and (B) LV mass index in
the overall study population.
Szwejkowski et al. JACC Vol. 62, No. 24, 2013
Allopurinol Reduces LV Mass in Patients With Type 2 Diabetes Mellitus December 17, 2013:2284–93
2290beneﬁcial effects on cardiac hypertrophy without the need
for decreasing blood pressure. The role of OS in the path-
ogenesis of diabetes is more controversial. Various studies
have suggested a role for OS underlying the development of
insulin resistance, b-cell dysfunction, and impaired glucose
tolerance (see Wright et al. [44]). Although we did not ﬁnd
a change in oxidized LDL, this does not preclude an effect
on OS as plasma biomarkers tend to change very little (if at
all) after allopurinol, whereas vascular tissue OS has been
shown to change profoundly following exposure to allopu-
rinol (29,30) (i.e., current plasma OS biomarkers may be
fairly insensitive in this situation with allopurinol). The
second possibility is that LVH might regress because of the
reduction in LV afterload, and some studies have found
allopurinol reduces AIx. However, we did not ﬁnd this in
our diabetic cohort. The third possibility is that allopurinol
might reduce BP. Although allopurinol had no effect on BP
in this study, this study was not powered to detect an effect
on BP as such, and it remains possible that some of the
LVH regression was caused by subtle changes in BP,
although no consistent trend was ever seen here (Table 6).
Although our study does not clarify the exact mechanism of
allopurinol’s effect on LVM in T2DM, it demonstrates
a potentially useful therapy that might reduce residual CV
risk in patients with T2DM.
In contrast to other patient groups, we found no effect of
allopurinol on endothelial function. The reason for the lack
of effect of allopurinol in this study might be that our
T2DM patients were well treated with statins, angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers, each of which is known to improve endothelial
function. Indeed, this was evident in the baseline measure-
ments of vascular health in our patients. The baseline
AIx was only 11%, and therefore, it may have made it
difﬁcult to improve it further with allopurinol. This notion is
generally supported by a previous study in which allopurinol
had no effect on endothelial function in healthy individuals
who had normal endothelial function at baseline (45).
Another reason why we were able to demonstrate an effect of
allopurinol on LVH but not on endothelial function in this
study may have been because we pre-selected those with
high baseline LVM, whereas abnormal endothelial function
Figure 5 LV Change by Median LVMI at Baseline
Histogram of change in (A) left ventricular mass (LVM) and (B) left ventricular
mass index (LVMI) in patients with above-median LVMI at baseline. LV ¼ left
ventricular.
Figure 6 Individual LV Change by Median LVMI at Baseline
Dot plot of change in (A) LVM and (Bi) LVMI in patients with above-median LVM or
LVMI at baseline. Abbreviations as in Figure 5.
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2291at baseline was not a prerequisite in this study: this was
because our primary endpoint was change in LVM.
The magnitude of the LVM changes produced here by
allopurinol is modest. We expect that the difference we saw
in LVM at 9 months would increase over the ﬁrst 2 years of
treatment, as this is usually the case with LVH regression
(46). Furthermore, in this study, LVH regression was
greater in those with higher baseline LVM, which suggests
that perhaps allopurinol should be focused toward this
higher-risk subgroup where its effect was much larger. It is
also worth noting that these results are entirely consistent
with the only 2 previous human studies, which assessed the
effect of allopurinol on LVH (22,23). It is inconceivable that
3 different studies produced the same result by chance.It is worth noting that the effect of allopurinol on gly-
cemia is controversial. At least 1 case report suggested that
allopurinol can induce new T2DM, whereas another large
database study suggested exactly the opposite effect (47).
Our study is the largest prospective study to date that has
investigated the effect of allopurinol on glycemic control in
T2DM. We have found that allopurinol has no effect on
glycemic control in T2DM.
We used the dosage of 600 mg/day because there appears
to be an important dose–response relationship with allopu-
rinol. A lot of previous research with allopurinol used a dose
of 300 mg once daily (48). However, 1 study showed that
increasing the dose of allopurinol from 300 to 600 mg
improved endothelial function by an additional 52%, such
that the allopurinol dose of 600 mg improved endothelial
function by 143% compared with placebo (29). Previous
studies using 300 mg of allopurinol might actually have used
Table 5
Change in Blood Parameters Over the 9-Month
Study Period
Parameter Placebo Allopurinol p Value
Hemoglobin, g/l 1.50  3.19 1.51  2.99 0.993
Creatinine, mm/l 7.00  13.88 7.67  7.39 0.910
eGFR over, ml/min/1.73 m2 6.57  11.75 8.78  10.00 0.441
Fasting glucose, mmol/l 0.84  4.05 0.41  3.64 0.668
Fasting insulin, mU/l 6.41  19.26 1.64  15.96 0.306
HbA1c, % 0.063  0.47 0.43  1.80 0.279
Urine PCR, mg/mmol 2.67  12.76 5.03  20.13 0.590
BNP, pg/ml 1.49  20.22 3.16  20.36 0.754
Uric acid (6 months),
mmol/l
0.019  0.12 0.27  0.17 <0.001
Uric acid (9 months),
mmol/l
0.01  0.06 0.25  0.18 <0.001
HS TropT, ng/l 0.34  2.98 0.35  2.25 0.656
Oxidized LDL, U/l 0.11  7.69 0.74  8.80 0.692
Values are mean  SD.
Abbreviations as in Table 1.
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2292a suboptimal dose of allopurinol. Allopurinol was well
tolerated in our study at this high dose. Allopurinol can be
given up to 800 or 900 mg/day, according to the U.S. Food
and Drug Administration and British National Formulary,
respectively. Reassuringly, we have also found that high-dose
allopurinol has no adverse effect on renal function in
T2DM.
Study limitations. The main limitation is the relatively
small number of patients recruited. It is almost inevitable
with so many demographic parameters that a few parameters
will by chance be different at baseline, although fewTable 6
Changes in Parameters of Endothelial Function,
Blood Pressure, and Body Mass Index
Parameter Placebo Allopurinol p Value
Ofﬁce SBP (6 months),
mm Hg
3.17  17.08 1.69  11.31 0.698
Ofﬁce SBP (9 months),
mm Hg
6.50  28.67 0.52  14.82 0.245
Ofﬁce DBP (6 months),
mm Hg
4.10  14.13 8.55  6.88 0.132
Ofﬁce DBP (9 months),
mm Hg
4.53  13.25 7.17  8.44 0.367
24hr SBP (9 months),
mm Hg
1.00  0.61 0.41  1.72 0.129
FMD hyperemia
(6 months), %
0.53  2.93 0.079  4.21 0.602
FMD hyperemia
(9 months), %
0.48  4.38 1.00  6.95 0.733
FMD GTN (6 months), % 1.42  5.43 0.11  1.21 0.405
FMD GTN (9 months), % 1.10  4.84 0.84  5.95 0.856
AIx (6 months), % 1.88  9.46 1.51  11.54 0.890
AIx (9 months), % 1.17  12.67 1.36  9.58 0.948
PWV (6 months), m/s 0.32  1.75 0.87  2.19 0.288
PWV (9 months), m/s 0.71  2.65 0.70  2.22 0.987
BMI (9 months) 0.31  8.11 0.04  9.66 0.520
Values are mean  SD.
BMI ¼ body mass index; GTN ¼ glycerol tri-nitrate; other abbreviations are as shown in Table 1.differences were statistically signiﬁcant. However, because of
the relatively small sample size, we cannot exclude the
possibility that some subtle demographic differences
between the 2 groups might have contributed to our results.
The baseline LVMI in this study was low. This was due in
part to the segmentation process, where the physicist actively
excluded “partial volume” (deﬁned as <50% full thickness
myocardium) areas at the extreme basal end of the ventricle.
The inclusion or exclusion of a single slice in this region is
known to alter the outcome value for the LVMI by typically
10%. However, the emphasis at all stages of this work was to
ensure optimized repeatability in order to maximize the
potential sensitivity of the primary endpoint (change in
LVMI).Conclusions
Allopurinol caused regression of LVH in patients with
T2DM and LVH at baseline. Regression of LVH has been
shown previously to reduce CV mortality and morbidity.
Therefore, allopurinol may become a useful therapy for
T2DM patients with LVH, especially in those with the
greatest LVH at baseline.
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APPENDIX
For complete details of the cardiac MRI protocol, please see the online
version of this article.
